Lectrolyst utilizes electrochemistry to convert waste CO2 and water into valuable chemical ingredients and edible protein, addressing the need for sustainable food production and greenhouse gas reduction. Their technology enhances resource efficiency by producing food with lower land, water, and fertilizer requirements compared to traditional methods.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of food production rely heavily on land, water, and fertilizers, contributing to environmental degradation and resource depletion. Traditional agriculture also struggles to efficiently convert resources into food, leading to significant waste and greenhouse gas emissions.
Solution
Lectrolyst is developing an electrochemistry-based system that converts waste carbon dioxide and water into valuable chemical ingredients and edible protein. This technology, termed "electro-agriculture," offers a more resource-efficient approach to food production compared to traditional photosynthesis-based methods. By utilizing electrochemistry, Lectrolyst aims to reduce the land, water, and fertilizer requirements associated with conventional agriculture, while also transforming a greenhouse gas into useful products. The system has been validated in simulated space missions and is being developed as part of a consortium to transform carbon dioxide into edible protein.
Target Audience
The primary target audience includes organizations and researchers focused on sustainable food production, resource efficiency, and greenhouse gas reduction, as well as space agencies interested in closed-loop life support systems.
Features
- Electrochemical conversion of CO2 and water into chemical ingredients and edible protein
- Reduced land, water, and fertilizer requirements compared to traditional agriculture
- Technology validated by NASA in simulated space missions
- Part of a consortium funded by the Bill & Melinda Gates Foundation and the Novo Nordisk Foundation